Sarcoma Research Studies

< Back to Young Adult Cancer Research Studies Page

Ewing Sarcoma New Diagnosis

A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

  • Ages: 6 Months to 21 Years  

To determine the safety of oral LOXO-292 in pediatric patients with advanced solid tumors: Dose limiting toxicities (DLTs) [ Time Frame: During the first 28-day cycle of LOXO-292 treatment ] LOXO-RET-18036:  A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric P ...More

Contact Us

Contact us.

To learn more about available sarcoma clinical trials, contact us at cancer@cchmc.org or 513-636-2799.